A carregar...
Tailoring front-line therapy in diffuse large B-cell lymphoma: who should we treat differently?
Although there have been significant insights into the biology of diffuse large B-cell lymphoma (DLBCL) over recent years, progress in our therapeutic approach has been disappointing over the same timeframe. This is not for want of trying. In 2017, R-CHOP (rituximab plus cyclophosphamide, doxorubici...
Na minha lista:
| Publicado no: | Hematology Am Soc Hematol Educ Program |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society of Hematology
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6142538/ https://ncbi.nlm.nih.gov/pubmed/29222268 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|